XNAS · ARAY
-5.45% · -$0.0100 · Vol 2.5M
Market closed · last close 4:00 PM ET · price as of 19:05:20 ET
Accuray Incorporated

Accuray Incorporated

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
$0.2396
Card
Relationship Map

Follow $ARAY

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ARAY by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
ARAY
Accuray Incorporated
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

37/ 100
Veridion Score
Lower range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ARAY moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ARAY catalysts
About Accuray Incorporated
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed since
2007
Employees
809
Country
US

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.2475
Day high
$0.2533
Day low
$0.2285
Previous close
$0.2534
52W high
$1.85
-87.05% from high
52W low
$0.2151
1% of range
Market cap
$30.3M
Beta
1.65
Shares out
119.4M
Volume
2.5M
0.18× rel vol
Avg volume
14M
VWAP
$0.2394
Price history computed in-house
1W
-14.73%
1M
-4.20%
3M
-0.70%
1Y
-87.05%
YTD
-70.94%
SMA 50 $0.2669 · below
SMA 200 $0.4250 · below
52W position 1%

ARAY overview

Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file
Loading financial statements
Loading ARAY Form 4 filings
Public disclosures

Congress activity in ARAY

No receipt-qualified filings found.

Federal contracts

ARAY contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ARAY in this window.
Lobbying spend

ARAY lobbying filings, year to date.

Registered lobbying filings matched to Accuray Incorporated.

$200.0K
Refresh interval: 12hSource: LDA disclosure filings
Medicare/Medicaid Trade (domestic/foreign)Trade (domestic/foreign) Medicare/Medicaid
Filing
$40.0K
ACCURAY INCORPORATED

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Jul 20, 2026
Filing
$40.0K
ACCURAY INCORPORATED

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Apr 17, 2026
Filing
$40.0K
ACCURAY INCORPORATED

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Mar 12, 2026
Loading news for ARAY
Analyst ratings
Sovereign unlock shows live analyst consensus for ARAY.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.